To evaluate whether variations in the IL1B gene could be associated with Graves' ophthalmopathy (GO) in patients with Graves' disease (GD).
G raves' disease (GD), with or without Graves' ophthalmopathy (GO), is an autoimmune disease characterized by hyperthyroidism, diffuse goiter, thyroid-specific autoantibodies, and dermopathy due to circulating autoantibodies. 1 GO is the most common extrathyroid manifestation of GD and affects 25% to 50% of GD patients. [2] [3] [4] [5] Approximately 28% of patients with GO present as severe cases, with restricted mobility, diplopia, keratopathy, and optic neuropathy. 6, 7 Several genes have been reported that promote the development of GO, including human leukocyte antigen (HLA) class I and class II molecules. 8 For example, the ϩ49G allele of cytotoxic Tlymphocyte-associated antigen-4 (CTLA4) confers genetic susceptibility to GO, although meta-analyses did not support this finding. CT60A/G of CTLA4 is one of the GD-associated polymorphisms that await further studies that examine their association with GO. In addition, polymorphisms in several immunomodulatory genes, such as the intron 1 (CA) repeat in interferon-␥ (IFNG); G238A, C863A, and T1031C in tumor necrosis factor-␣ (TNFA); and A1405G in intracellular adhesion molecule-1 (ICAM1), have been reported to increase susceptibility to GO. 8 The combination of specific alleles among these genes would make the patient susceptible to GO.
Interleukin-1 beta (IL1B), a proinflammatory cytokine expressed by activated macrophages and several other types of cells, is thought to play a crucial role in the pathogenesis of autoimmune diseases. 9, 10 IL1␤ was initially known as one of the lymphocyte activating factors (LAFs), owing to its role in the induction of T-cell proliferation and maturation. 9, 10 Recent studies have demonstrated that IL1␤ released by macrophages and fibroblasts can induce adipogenesis and accumulation of glycosaminoglycans (GAGs) and prostaglandin E2 (PGE2), which may result in the development of GO. 8, 11, 12 One study revealed that the singlenucleotide polymorphism (SNP) Ϫ511C of IL1B is associated with GO, whereas others did not. [13] [14] [15] Although the connection between IL1B polymorphism and GO remains controversial, several studies have demonstrated that polymorphisms of IL1B may correlate with IL1␤ expression in other diseases. 16 -18 In addition, IL1␤ promotes the accumulation of GAGs through the upregulation of hyaluronan synthesis and accumulation of PGE2, stimulates adipogenesis, and hyperinduces the expression of interleukin (IL)-6 and -8 and macrophage chemoattractant protein (MCP)-1 in orbital fibroblasts derived from healthy individuals and patients with GO. 8,19 -23 Moreover, the polymorphisms of the IL1 family are involved in several autoimmune diseases such as systemic lupus erythematosus (SLE), 24 -26 rheumatoid arthritis, 27, 28 autoimmune hemolytic anemia, 29 and GD. 30 These reports support that IL1B is a potential candidate gene in the development of GO.
Although previous reports have suggested that IL1B polymorphisms and expression lead to autoimmune diseases, 24 -30 the genetic role of IL1B in GO remains to be elucidated. In the present study, we investigated SNPs in IL1B that may be protective against or causative of GO in Taiwan Chinese patients with GD.
METHODS

Patients and Healthy Individuals
A group of 484 patients with a confirmed diagnosis of GD and a control group of 160 healthy volunteers at China Medical University Hospital in Taiwan were enrolled and actively observed. All individuals in this study provided informed consent, as approved by the ethics committee of China Medical University Hospital and in accordance with the guidelines in the Declaration of Helsinki.
Patients. Diagnosis of GD was based on the typical clinical features of hyperthyroidism: diffuse enlargement of the thyroid gland, increased free thyroxine or triiodothyronine levels, suppressed thyroid-stimulating hormone levels, positive thyrotrophin-receptor autoantibodies, and the presence (or absence) of anti-thyroid peroxidase (anti-TPO) antibodies or antithyroglobulin antibodies. Information regarding sex, age at onset of GD, treatment of hyperthyroidism, personal history of cigarette smoking, history of systemic diseases, and family history of autoimmune thyroid disease was obtained. The inclusion criteria were (1) meeting the diagnostic criteria of GD at the time of examination; (2) being willing to participate and capable of giving informed consent; and (3) being a self-reported nonaboriginal Taiwanese with no parent or grandparent having an aboriginal background. The exclusion criteria were (1) being unable to understand or give informed consent or (2) being pregnant or having given birth within 1 year, to exclude the possibility of including subjects with postpartum thyroiditis. Patients with GO (GD/GO) were identified according to the following criteria: Normal upper eyelid position was 1.5 mm below the superior limbus, and normal lower eyelid position was at the level of the inferior limbus in primary gaze. Proptosis was measured by a Hertel exophthalmometer and was defined as the anteroposterior protrusion of the globe Ͼ19 mm from the lateral orbital rim in either eye or any discrepancy in the degree of protrusion of the two eyes by Ͼ1 mm. All individuals classified as affected were interviewed and examined by experienced clinicians. A full medical record review was conducted to obtain demographics (age and sex); history of tobacco use; recurrence of GD (patients with GD who have accepted medical treatment); and progression (patients with ongoing GD), treatment, and clinical features of the condition.
Healthy Individuals. The healthy group was matched for sex according to the female predominance of GD, including 32 men (20.0%) and 128 women (80.0%). Age was significantly different between the groups of healthy volunteers (27.4 Ϯ 6.4 years) and patients with GD (39.9 Ϯ 12.2 years; P ϭ 1.028 ϫ 10 Ϫ34 ).
All blood samples were collected from consenting individuals by venipuncture for subsequent genomic DNA isolation. Data are n (%), unless otherwise indicated. Bold probabilities are statistically significant. * Age and myxedema were determined by Mann-Whitney U test. † All characteristics except age, goiter, and myxedema were determined by 2 test using 2 ϫ 2 contingency tables. ‡ Smoking category includes former, current, and ever smoker categories. § Goiter was determined by chi-square test using 2 ϫ 5 contingency tables. P Ͻ 0.05 was statistically significant.
SNP Selection
Institute, Massachusetts Institute of Technology, Cambridge, MA), and Tag SNPs were selected by using the Tagger function and applying the following additional criteria: (1) a threshold minor allele frequency (MAF) in the HapMap CHBϩJPT population of 0.10 for tag SNPs and (2) a genotyping score (Illumina, Inc., San Diego, CA) more than or equal to 0.6, as recommended by the manufacturer, to ensure a high genotyping success rate. Eight polymorphisms in the IL1B gene met the criteria and were selected, including the SNPs rs3917368 (A/G at 3Ј UTR), rs2853550 (C/T at 3Ј UTR), rs1143643 (A/G at intron 6), rs1143634 (C/T at exon 5, known as ϩ3954A/G and ϩ3962A/G), rs1143630 (A/C at intron 3), rs1143627 (C/T at 5Ј-UTR, known as Ϫ31C/T), rs16944 (C/T at 5Ј-UTR, known as Ϫ511C/T), and rs12621220 (C/T at 5Ј-UTR).
Genomic DNA Extraction and Genotyping
All blood samples from individuals were collected by venipuncture for genomic DNA isolation. The genomic DNA was extracted from peripheral blood leukocytes (Genomic DNA kit; Qiagen, Valencia, CA) in accordance with the manufacturer's instructions. DNA concentration was quantified in all samples before genotyping. Thirteen of the 484 samples were excluded in this study because the amount of DNA was not enough to perform the assay. All eight single-nucleotide polymorphisms (SNPs) in IL1B were genotyped with an allele-specific extension and ligation assay according to the manufacturer's instructions (Illumina).
IL1␤ Quantitative Measurement
The plasma IL1␤ level was measured by using a quantitative enzymelinked immunosorbent assay according to the manufacturer's instructions (eBioscience, San Diego, CA).
Statistical Analysis
Associations between each SNP and disease were assessed by 2 test. Allele and genotype frequencies in cases and controls were compared and odds rations (ORs) per SNP were estimated by applying unconditional logistic regression. Alleles and genotype frequencies of alleles, genotypes, haplotypes, and diplotypes were expressed as a percentage of the total number of alleles, genotypes, haplotypes, and diplotypes. Results reaching P Ͻ 0.05 were statistically significant. The OR, with the 95% confidence interval (CI), was calculated from the genotype and allelic frequencies. Associations between each SNP and IL1␤ plasma levels were assessed by Student's t-test (for two-category variable) or ANOVA (for a three or more category variable; SPSS for Windows, ver., 14.0; Chicago, IL). Haplotypes were inferred by using Phase 2.1, a computational tool based on Bayesian methods. 31 Linkage disequilibrium (LD) was performed with Haploview 4.1. 31 The multifactor dimensionality reduction (MDR) 1.1.0 of the open-source MDR software package (Dartmouth Medical School, Hanover, NH) was used to detect the best locus-locus interaction models with an estimated testing accuracy of Ͼ50% consistency. The interaction dendrogram was established according to a hierarchical clustering algorithm.
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RESULTS
Basic Characteristics of Patients with GD and Correlation between the Factors
The demographics and clinical information of the participants are summarized in Table 1 . We also examined the association of GO with age, sex, smoking status, recurrence, treatment, and clinical features. The 2 test and Mann-Whitney U test revealed that sex, smoking status, and radioiodine therapy were significantly associated with GO among patients with GD.
Allele and Genotype Frequencies of the IL1B Polymorphisms
To identify the SNPs associated with GO, we genotyped eight SNPs in IL1B. As comparing with healthy individuals, the * Allele frequencies were determined by 2 test using 2 ϫ 2 contingency tables. † OR and 95% CI per allele were estimated by applying unconditional logistic regression. The major allele was used as the reference. P Ͻ 0.05 is statistically significant. presence of the C allele of SNP rs1143643 may increase the risk of GD (P ϭ 1.655 ϫ 10 Ϫ112 ) and GO (P ϭ 1.414 ϫ 10 Ϫ57 ), although all eight allele distributions of the IL1B polymorphisms did not differ significantly between GD patients with or without GO (Table 2) . Table 3 summarizes the genotype distributions of the IL1B polymorphisms in all individuals. The T/T genotype of SNP rs1143634 was present only in healthy individuals, and the T/T genotype of SNP rs16944 was less frequent in patients with GD (P ϭ 0.041). In addition, the A/A genotype of SNPs rs3917368 and rs1143643 may increase the risk of GO among patients with GD (P ϭ 0.024 and P ϭ 0.017, respectively). The interaction dendrogram of the eight SNPs in the IL1B gene were constructed with the MDR software, and the results revealed a strong interaction of the rs3917368 and rs1143643 loci in the IL1B gene in modulating the risk of GO (Fig. 1) . These results suggest that patients with the T/T genotype at SNPs rs1143634 and rs16944 have a lower risk of developing GD. In addition, patients with the A/A genotype of SNPs rs3917368 and rs1143643 may have a higher risk of developing GO.
Haplotype Frequencies of the IL1B Polymorphisms
Combination of the eight selected SNPs in IL1B by tagging SNPs in the HapMap CHBϩJPT population may represent different IL1B haplotypes. In addition, MDR analysis indicated that the best interaction model for predicting the development of GO is the eight-locus model composed by all eight SNPs analyzed in the present study (testing accuracy, 63.9%; cross-validation consistency, 100/100; P Ͻ 0.0001). Therefore, we determined the haplotypes in the eight SNPs that had frequencies of Ͼ5% and identified the 13 haplotypes shown in Table 4 ). Ht3-GCGCACTT, Ht5-ACACACTT, and Ht6-GTGCCCTC were found only in patients with GD, whereas Ht9-ACATCTTC, Ht10-ACATCTCC, Ht11-GCGCCCCT, Ht12-ACACCTTC, and HT13-GCGTCCCT were found only in the healthy individuals. Haplotypespecific analysis showed that the Ht1-ACACCTCC and Ht2-GCGCCCTT haplotypes may increase the risk of GD (P ϭ 1.241 ϫ 10 Ϫ44 and 7.388 ϫ 10 Ϫ8 ; OR, 21.599 and 3.917; 95% CI, 12.221-38.175 and 2.304 -6.658, respectively) compared with the risk in healthy individuals. Ht4-GCGCCTCC may reduce the risk of GO among the patients with GD (P ϭ 0.025; OR, 0.502; 95% CI, 0.273-0.925). Table 5 showed that 141 patients with GD bore the diplotype A-A/A-A, and it appeared more frequently in patients with GO than did A-A/G-G or G-G/G-G (P ϭ 0.008; OR, 1.650; 95% CI, 1.141-2.384). In 419 patients with GD, the non-Ht4/non-Ht4 diplotype was less frequently found in the patients who also had GO compared with at least one Ht4 haplotype (diplotypes Ht4/Ht4 and Ht4/non-Ht4, P ϭ 0.007; OR, 0.414; 95% CI, 0.214 -0.797). These findings confirm that the results from genotype and haplotype analysis. In addition, the LD plots of IL1B in the healthy individuals and GD patients with or without GO showed an apparent variation in these polymorphisms (Fig. 2) . These observations suggest that Ht1-ACACCTCC and Ht2-GCGCCCTT haplotypes put the individual at risk for the development of GD, whereas Ht4-GCGCCTCC may play a protective role against the development of GO.
GO-Associated IL1B Polymorphisms Related to Circulating IL1␤ Levels among Patients with GD
We performed enzyme-linked immunosorbent assays on plasma proteins from 432 of 471 GD patients and examined their association with IL1B genotypes and diplotypes ( Table 6 ). The mean plasma IL1␤ concentration in patients with GO was 181.5 Ϯ 580.1 pg/mL, which was significantly higher than in those without GO (88.8 Ϯ 190.9 pg/mL, P ϭ 0.038). Stratified analysis showed that patients with Ht4-GCGCCTCC had much lower concentrations of IL1␤ (P ϭ 0.042). Although patients with the A-A/G-G and G-G/G-G diplotypes of the SNPs rs3917368 and rs1143643 are less susceptible to GO (GO versus nonGO, 45.9% vs. 57.8%, respectively), they had unexpectedly higher IL1␤ concentrations than did those with the A-A/A-A diplotype (P ϭ 0.029). Genotype analysis is consistent with the observation. Our results demonstrated that higher circulating IL1␤ concentrations may correlate with GO development. The GO-protective haplotype Ht4-GCGCCTCC may be used to predict IL1␤-induced GO in patients with GD. However, patients with A-A/G-G and G-G/G-G, although less susceptible to GO, may have higher plasma IL1␤ concentrations than do those with A-A/A-A. These findings imply that the involvement of IL1␤ in GO development may be more than the IL1B polymorphism-associated circulating IL1␤ elevation in patients with GD.
DISCUSSION
We found that the SNPs rs3917368 and rs1143643 in the 3Ј UTR and intron regions of IL1B, respectively, may be risk genotypes for development of GO. Persons with the genotypes containing both rs3917368 A/A and rs1143643 A/A may bear a * Order of SNPs comprising the IL1B haplotypes: rs3917368, rs2853550, rs1143643, rs1143634, rs1143630, rs1143627, rs16944, and rs12621220. The haplotypes were identified by the Bayesian statistical method available in the program Phase 2.1. † Global test for haplotype frequency in relation to GD or GO development was determined by 2 test using 2 ϫ n contingency tables (where n is 13 ϩ1 (haplotype Ͼ5% plus remaining haplotypes). P Ͻ 0.05 is statistically significant. ‡ Individual haplotype frequency in relation to GD or GO development was determined by 2 test using 2 ϫ 2 contingency tables. P Ͻ 0.05 is statistically significant. § OR and 95% CI for genotypes were estimated by applying unconditional logistic regression.
higher risk of developing GO. Clinical association studies showed that the presence of the A-A/A-A diplotype was significantly associated with a higher risk of GO, but the presence of the diplotype along with the Ht4-GCGCCTCC haplotype may be protective against GO. In addition, the circulating IL1␤ concentrations have been analyzed in GD patients and the association with GO as well as genotypes have been made. Our results showed that IL1B polymorphisms may be associated with the level of circulating IL1␤ as well as GO development in patients with GD. Several reports have predicted the genetic association of IL1B with the development of GD and GO. Hayashi et al. 36 found a significant association between GD and the Ϫ31T (rs1143627) allele in the promoter region in their study of the Japanese population. Liu et al. 13 found an association between Ϫ511C/T (rs16944) and GD with GO in China, whereas Lacka et al. 14 and Khalilzadeh et al. 15 did not find an association between the IL1B polymorphisms -511C/T (rs16944) and ϩ3954 C/T (rs1143634) and GO in their studies in Iran and Poland, respectively. We found that the C allele of ϩ3954 (rs1143634) is related to the development of GD and GO. In addition, the T/T genotype of Ϫ511 (rs16944) is related to less susceptibility to GD. However, in the present study, the genotypes Ϫ31C/T (rs1143627) and -511C/T (rs16944) were not associated with the development of GO. The effect of population differences in the determination of such associations should not be underestimated. In the present study, for the first time, we found the association between A/A genotypes of rs3917368 and rs1143643 and the risk for GO, although the significance was weak. Although we identified haplotypes with the Phase program, we found much more diverse haplotype distribution in healthy individuals than in the patients with GD. In addition, patients with GO had more similar haplotype distribution than did those without GO. This observation is † Significance of diplotype in relation to GO development was determined by applying multifactor dimensionality reduction (MDR) models. P Ͻ 0.05 was statistically significant. ‡ ORs and 95% CIs for A™A/A™A and non A™A/A™A was estimated by applying multifactor dimensionality reduction (MDR) models. § Genotype frequencies were determined by 2 test using 2 ϫ 2 or 2 ϫ 3 contingency tables. P Ͻ 0.05 was statistically significant. ORs and 95% CIs for non-Ht4/non-Ht4 (reference) and Ht4/Ht4 and Ht4/non-Ht4 was estimated by applying unconditional logistic regression. Recent studies have shown that a positive feedback cycle composed of mechanical, immunologic, and cellular processes is involved in the development of GO. 8, 21, 22 Interstitial accumulation of GAGs, PGE2, and adipogenesis in the orbital tissue contributes to GO in GD patients and these observations and a series of thyroid-related factors, such as the thyrotropin receptor antigen, are thought to be a consequence of the release of certain cytokines, including IL1␤, from T cells, monocytes, and activated fibroblasts. 8, [21] [22] [23] 37 Polymorphisms may cause alternations in the expression and function of IL1B, 16 -18 which may affect the downregulation of T-cell activation and the subsequent inflammatory diseases, autoimmune diseases, cancer, and GAG accumulation. Given the important role of T cells in the pathogenesis of GO, IL1B may be a candidate gene for the induction of these autoimmune reactions. Our results demonstrated that GO patients have higher plasma IL1␤ levels than those without GO, which supports this hypothesis.
Although our hypothesis was that polymorphisms of IL1B relate to the development of GO in patients with GD, the Ϫ31C and Ϫ511T of IL1B, the polymorphism associated with decreased and increased transcriptional activity, 38, 39 were associated with neither IL1␤ levels nor GO development in our study. We found that the Ht4-GCGCCTCC is related to lower circulating IL1␤ concentration and less susceptibility toward GO, indicating that Ht4-GCGCCTCC may be used to predict the IL1␤-induced GO in patients with GD. However, the A-A/G-G and G-G/G-G diplotypes (less susceptible for GO were related to high circulating levels of IL1␤. It is notable that the IL1␤ concentration examined in our patients (0 -3.843 ng/mL) was lower than the IL1␤ dosage most used in the in vitro experiments (10 ng/mL), 19, 20, 40, 41 and the outliers (IL1␤ Ͼ1 ng/mL)
were only the patients with the A-A/G-G genotype. Although plasma IL1␤ in healthy individuals is yet to be determined, it would be interesting to know whether there are critical dosedependent levels of IL1␤ in protection against or promotion of the development of GO. The linkage among the IL1B polymorphisms, IL1␤ level, and GO development should be further confirmed in studies with larger samples. In the present study, our results suggest that IL1B genotypes are associated with the development of GO, the most common orbital disease in GD. This report provides evidence from examination of patient outcomes that polymorphisms of the IL1B gene may predict the development of GO. Data are expressed as mean Ϯ SD plasma IL1␤ levels (in picograms/milliliter), with the number of subjects in parentheses. P Ͻ 0.05 is statistically significant (data in bold).
* Significance of genotypes and haplotypes toward plasma IL1␤ levels or plasma IL1␤ levels in relation to GO development in all patients with GD were determined by Student's t-test or ANOVA, as suitable.
† Significance of each genotype or haplotype in relation to plasma IL1␤ levels in all patients with GD were determined by Student's t-test.
‡ Significance of genotypes and haplotypes in relation to plasma IL1␤ levels in patients with or without GO were determined by ANOVA.
